|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, May 27, 2016 ) Publisher's, 'Glucose Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) - Product Pipeline Review - 2016', provides an overview of the Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119)'s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Other Key Points in Report:
- The report provides a snapshot of the pipeline therapeutic landscape of Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119)
- The report provides overview of Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119)'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119)'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Ask for Sample Report @ http://www.reportsweb.com/inquiry&RW0001242088/sample
Table of Content: An Overview
Table of Contents 2
List of Tables 6
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) Overview 8
Therapeutics Development 9
Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) - Products under Development by Stage of Development 9
Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) - Products under Development by Therapy Area 10
Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) - Products under Development by Indication 11
Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) - Products under Development by Companies 14
Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) - Products under Development by Universities/Institutes 16
Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) - Therapeutics Assessment 18
Assessment by Monotherapy/Combination Products 18
Ask for Discount on Report @ http://www.reportsweb.com/inquiry&RW0001242088/discount
Assessment by Mechanism of Action 19
Assessment by Route of Administration 20
Assessment by Molecule Type 21
Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) - Companies Involved in Therapeutics Development 22
Amgen Inc. 22
Array BioPharma Inc. 23
Astellas Pharma Inc. 24
CymaBay Therapeutics, Inc. 25
Daiichi Sankyo Company, Limited 26
F. Hoffmann-La Roche Ltd. 27
GlaxoSmithKline Plc 28
Hyundai Pharmaceutical Co., Ltd. 29
LG Life Science LTD. 30
Merck & Co., Inc. 31
Neurocrine Biosciences, Inc. 32
Novartis AG 33
Rhizen Pharmaceuticals S.A. 34
Sanwa Kagaku Kenkyusho Co., Ltd. 35
Takeda Pharmaceutical Company Limited 36
Yuhan Corporation 37
Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) - Drug Profiles 38
17-i - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Purchase Complete Report @ http://www.reportsweb.com/buy&RW0001242088/buy/3500
About Us:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.
Contact Us:
Email: sales@reportsweb.com
Call: +1-646-491-9876
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
